What are the Therapeutic Approaches Targeting RTKs?
Targeting RTKs has become a significant strategy in cancer therapy. There are two main approaches: small molecule inhibitors and monoclonal antibodies. Small molecule inhibitors, like Erlotinib and Gefitinib, target the kinase domain of RTKs and prevent their activation. Monoclonal antibodies, such as Trastuzumab and Cetuximab, bind to the extracellular domain of RTKs, blocking ligand binding and receptor dimerization.
